ArticleOncogene2026
Dual novel compounds destroy mitochondrial morphology and function to treat glioblastoma by promoting the p62-mediated protein degradation of mitochondrial respiratory chain complex.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Therapeutic efficacy of temozolomide (TMZ) remains limited, and GBM patients generally experience poor outcomes due to the presence of multiple mechanisms of TMZ resistance. Previously, we developed two novel compounds: EPIC-1027, which targets HOTAIR/PRC2 complex, and EPIC-1042, which disrupts interaction between PTRF and CAV1. In this study, we aim to establish a novel combinatorial strategy for GBM by targeting mitochondrial function. Proteomics was employed to evaluate global protein alterations induced by EPIC-1027 and EPIC-1042. Super-resolution microscopy and transmission electron microscopy were used to characterize changes in mitochondrial morphology. Metabolic flux analysis was performed to assess alterations in cellular energy metabolism following combined treatment. An intracranial GBM model was established to validate the anti-GBM efficacy of EPIC-1027 and EPIC-1042 in vivo. Combined treatment with EPIC-1027 and EPIC-1042 reduced the abundance of respiratory chain complex proteins by promoting p62-dependent protein degradation, resulting in severe mitochondrial damage. Both glycolytic activity and oxidative phosphorylation were markedly suppressed following EPIC-1027 and EPIC-1042 treatment. In vitro, EPIC-1027 and EPIC-1042 exerted a synergistic inhibitory effect on GBM cell proliferation and significantly induced apoptosis in an MGMT-independent manner. In vivo, combined treatment with EPIC-1027 and EPIC-1042 significantly attenuated tumor growth and prolonged survival in mice bearing orthotopic GBM. Our study demonstrates that combined treatment with EPIC-1027 and EPIC-1042 induces mitochondrial structural abnormalities and functional impairment, leading to suppressed proliferation and enhanced apoptosis. These findings identified a novel combinatorial therapeutic strategy targeting mitochondria for the treatment of glioblastoma.
Identifiers
42888223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.